A retrospective analysis of mature T- and NK-cell lymphomas

• Junlei Jia,
• Xiaohui Wang,
• Zheng Song,
• Shen Meng,
• Yue Fei,
• Jingwei Yu,
• Xia Liu,
• Xue Han,
• Lanfang Li,
• Lihua Qiu,
• Zhengzi Qian,
• Shiyong Zhou,
• Wenchen Gong,
• Bin Meng,
• Xiubao Ren,
• Xianhuo Wang,
• Huilai Zhang

Affiliations

Junlei Jia

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Xiaohui Wang

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Zheng Song

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Shen Meng

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Yue Fei

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Jingwei Yu

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Xia Liu

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Xue Han

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Lanfang Li

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Lihua Qiu

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Zhengzi Qian

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Shiyong Zhou

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Wenchen Gong

Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China

Bin Meng

Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China

Xiubao Ren

Department of Immunology/Biotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China

Xianhuo Wang

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Huilai Zhang

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China